La vendita allo scoperto per Compass Pathways dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Compass Pathways. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Compass Pathways (NASDAQ:CMPS) Azioni, Report sulle vendite allo scoperto

Compass Pathways

Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.

COMPASS Pathways Plc - American Depository Shares

Compass Pathways PLC

Opportunities to invest in psychedelic stocks are emerging for those willing to get in early, and the 4 largest psychedelic compound-based portfolio drug discovery companies are up 5.9% in the past week.

Largest Psychedelic Compound -Based Clinical-Stage Drug Stocks Up 6% Last Week

Despite a rocky start in August, investor sentiment has remained resilient, with the S&P 500 rallying nearly 9% since its August 5th low. This upwa...

Morgan Stanley Predicts up to 220% Jump for These 2 'Strong Buy' Stocks

Compass Therapeutics files $300M mixed securities shelf

Psychedelic Stock Deep Dive: Atai Life Sciences

The psychedelic compound-based drug market is expected to triple over the next few years which should create many winning stocks in the years to come and, to monitor their progress we present a Portfolio of the 4 largest such companies.

Our Psychedelic Compound-Based Clinical-Stage Drug Stocks Portfolio Was Down 16% In August

RBC Capital analyst Leonid Timashev maintained a Buy rating on COMPASS Pathways (CMPS – Research Report) today and set a price target of $23.00. Th...

RBC Capital Remains a Buy on COMPASS Pathways (CMPS)

While the psychedelic compound-based drug market is expected to triple over the next few years which should create many winning stocks in the years to come, the stocks of the companies involved are having growing pains.

Psychedelic Compound-Based Drug Stocks Portfolio -13% W/e Sept. 6th

The psychedelic compound-based drug market is expected to triple over the next few years, creating many winning stocks in the years to come.

Psychedelic Drug Stocks +6% Last Week Vs. -13% Previous Week

BTIG analyst Thomas Shrader has maintained their bullish stance on CMPS stock, giving a Buy rating on September 10. Thomas Shrader has given his Bu...

Buy Rating Affirmed for COMPASS Pathways Amid Promising Psilocybin Treatment Prospects and Strategic Market Positioning

COMPASS Pathways files for mixed shelf offering

ATAI

CMPS

GHRS

MNMD

RCKT

News

Press Releases

Compass Pathways to announce first quarter financial results on May 8, 2024

Health Care

Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder

Comments

Compass Pathways

Vendite allo scoperto

Compass Pathways (NASDAQ:CMPS) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO